A key issue in anticancer drug development is how best to select and evaluate potential combinations of the rapidly growing number of molecularly targeted drugs. Dancey and Chen consider development strategies for targeted-agent combinations, highlighting challenges for their rational preclinical and clinical evaluation, and discussing possible approaches to overcoming them.
- Janet E. Dancey
- Helen X. Chen